Tyra Biosciences (NASDAQ:TYRA) Sets New 1-Year High – What’s Next?

Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) hit a new 52-week high during trading on Thursday . The company traded as high as $35.96 and last traded at $35.27, with a volume of 6161094 shares traded. The stock had previously closed at $33.01.

Analyst Upgrades and Downgrades

TYRA has been the topic of a number of research reports. HC Wainwright upped their target price on shares of Tyra Biosciences from $30.00 to $45.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Cantor Fitzgerald began coverage on Tyra Biosciences in a research report on Tuesday, February 24th. They set an “overweight” rating for the company. Wedbush upped their price target on Tyra Biosciences from $37.00 to $53.00 and gave the company an “outperform” rating in a research note on Friday, February 13th. Piper Sandler increased their price target on shares of Tyra Biosciences from $33.00 to $42.00 and gave the company an “overweight” rating in a research report on Friday, January 23rd. Finally, William Blair started coverage on shares of Tyra Biosciences in a research note on Tuesday, February 10th. They set an “outperform” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Tyra Biosciences has a consensus rating of “Moderate Buy” and an average price target of $42.33.

Tyra Biosciences Stock Up 1.4%

The company’s fifty day moving average price is $30.25 and its two-hundred day moving average price is $21.12. The company has a market cap of $1.89 billion, a price-to-earnings ratio of -17.43 and a beta of 1.06.

Tyra Biosciences (NASDAQ:TYRA) last issued its quarterly earnings data on Monday, March 2nd. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.03). On average, equities research analysts predict that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current fiscal year.

Insider Transactions at Tyra Biosciences

In other Tyra Biosciences news, Director Robert J. More sold 10,000 shares of Tyra Biosciences stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $25.00, for a total value of $250,000.00. Following the sale, the director owned 3,823,425 shares of the company’s stock, valued at $95,585,625. This trade represents a 0.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 15.20% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Federated Hermes Inc. grew its holdings in shares of Tyra Biosciences by 586.3% during the third quarter. Federated Hermes Inc. now owns 2,155 shares of the company’s stock worth $30,000 after buying an additional 1,841 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Tyra Biosciences in the 4th quarter valued at approximately $51,000. Chung Wu Investment Group LLC acquired a new position in Tyra Biosciences during the 4th quarter worth approximately $53,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Tyra Biosciences by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,594 shares of the company’s stock worth $68,000 after acquiring an additional 534 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Tyra Biosciences by 14.5% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock worth $126,000 after acquiring an additional 1,668 shares in the last quarter. 84.14% of the stock is owned by institutional investors and hedge funds.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.